Fact Sheet for Patients, ParentsAnd Caregivers Emergency ...
Fact Sheet for Patients, ParentsAnd Caregivers Emergency Use Authorization (EUA) of EVUSHELD™ (tixagevimab co-packaged with cilgavimab) for Coronavirus Disease 2019 (COVID-19) You are being given this Fact Sheet because your healthcare provider believes it is necessary to provide you with EVUSHELD (tixagevimab co-packaged with cilgavimab)
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
SYMBICORT Medication Guide
den8dhaj6zs0e.cloudfront.netSYMBICORT comes in 2 strengths. Your healthcare provider has prescribed the strength that is best for you. Note the differences between SYMBICORT and your other inhaled medications, including the differences in prescribed use and physical appearance.
Imfinzi Full Prescribing Information
den8dhaj6zs0e.cloudfront.netlung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. (1.1) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). (1.2)
Lynparza Prescribing Information
den8dhaj6zs0e.cloudfront.net5.4 Venous Thromboembolic Events 6 ADVERSE REACTIONS 6.1 Clinical Trial Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Use with Anticancer Agents 7.2 Effect of Other Drugs on Lynparza 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.5 Geriatric Use 8.6 Renal Impairment
Information, Prescribing, Pregnancy, Prescribing information, Thromboembolic
BREZTRI Full Prescribing Information
den8dhaj6zs0e.cloudfront.netIf the inhaler has not been used for more than 7 days, is dropped, or after weekly . cleaning, prime the inhaler again by releasing 2 sprays into the air away from the face, shaking well before each spray. 2.3 Dose counter. BREZTRI AEROSPHERE canister has an attached dose indicator, which indicates . how many inhalations remain.
Information, Prescribing, Dose, Prescribing information, Inhaler
SYMBICORT Prescribing Information
den8dhaj6zs0e.cloudfront.net5.18 Hypokalemia and Hyperglycemia. 6 ADVERSE REACTIONS. 6.1 Clinical Trials Experience in Asthma 6.2 Clinical Trials Experience in Chronic Obstructive Pulmonary Disease. 6.3 Postmarketing Experience. 7 DRUG INTERACTIONS. Antidepressants 7.3 Beta-Adrenergic Receptor Blocking Agents 7.4 Diuretics. 8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy …
US-56427 ---------------------------- DOSAGE AND ...
den8dhaj6zs0e.cloudfront.netnot start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG). (5.1, 6.1) • If: possible, manage bleeding without discontinuing ----- BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events. (5.4) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS IN PATIENTS WITH ACS ...
Farxiga Prescribing Information
den8dhaj6zs0e.cloudfront.netpatients with polycystic kidney disease or patients requiring or with a recent . history of immunosuppressive therapy for the treatment of kidney disease. FARXIGA is not expected to be effective in these populations. (1)----- DOSAGE AND ADMINISTRATION ----- • Assess volume status and correct volume depletion before initiating. ...
Information, Disease, Prescribing, Kidney, Prescribing information, Kidney disease, Polycystic, Polycystic kidney disease
FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE ...
den8dhaj6zs0e.cloudfront.netHealthcare Providers for detail on preparation and administration. (2) ... registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which EVUSHELD belongs (i.e., anti-infectives).
CRESTOR PRESCRIBING INFORMATION
den8dhaj6zs0e.cloudfront.netreduce elevated total-C, LDL-C, ApoB, nonHDL-C, and TG levels and to increase HDL-C (1.1) ... Monitor INR frequently until stable upon initiation or alteration of CRESTOR therapy. (5.4, 7.6) • Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (≥1 g/day)
Saphnelo full Prescribing Information
den8dhaj6zs0e.cloudfront.netwith severe active lupus nephritis or severe active central nervous system lupus. Use . of SAPHNELO is not recommended in these situations. (1)----- DOSAGE AND ADMINISTRATION -----The recommended dosage is 300 mg as an intravenous infusion over a 30-minute . …
Related documents
The Alberta Mental Health Act - CMHA National
alberta.cmha.caWhat will this guide tell me? defend someone's cause • The Alberta Mental Health Act: A Guide for Mental Health Service Users and Caregivers was written to help you understand some of the main actions permitted under the Act, how the Act might affect you, …
Health, Guide, Alberta, Mental, Caregivers, The alberta mental health act
FACT SHEET FOR PATIENTS, PARENTS AND CAREGIVERS …
www.regeneron.comFACT SHEET FOR PATIENTS, PARENTS AND CAREGIVERS. EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COV. TM (casirivimab and imdevimab) FOR CORONAVIRUS DISEASE 2019 (COVID-19) You are being given a medicine called REGEN-COV (casirivimab and imdevimab) for the treatment or post-exposure prevention of coronavirus …
Patients, Parents, Caregivers, For patients, Parents and caregivers